Related Experiment Video
Updated: Jul 16, 2026

Developing a Clinically Relevant Hemorrhagic Shock Model in Rats
Published on: March 22, 2024
[Post-partum hemorrhage: new therapeutic options]
1Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera, Verona. massimo.franchini@azosp.vr.it
Bleeding remains a major cause of morbidity and mortality in obstetrics. Recombinant activated factor VII (rFVIIa), which was originally developed for the treatment of bleeding in hemophilic patients with inhibitors, has been recently employed to prevent or control bleeding in several other non-hemophilic bleeding conditions. Among the newer, "off-label" clinical applications of rFVIIa, its use in the treatment of obstetrical bleeding unresponsive to conventional therapy has generated intense interest. The existing literature on the use of rFVIIa in post-partum hemorrhage (PPH) is analysed in this review. Although supported by few and uncontrolled studies, on the whole the published data suggest a potential role of rFVIIa in the management of PPH. However, further evidences are needed in order to better assess the optimal dose, the effectiveness and the safety of rFVI-Ia in such critical bleeding conditions.
Bleeding remains a major cause of morbidity and mortality in obstetrics. Recombinant activated factor VII (rFVIIa), which was originally developed for the treatment of bleeding in hemophilic patients with inhibitors, has been recently employed to prevent or control bleeding in several other non-hemophilic bleeding conditions. Among the newer, "off-label" clinical applications of rFVIIa, its use in the treatment of obstetrical bleeding unresponsive to conventional therapy has generated intense interest. The existing literature on the use of rFVIIa in post-partum hemorrhage (PPH) is analysed in this review. Although supported by few and uncontrolled studies, on the whole the published data suggest a potential role of rFVIIa in the management of PPH. However, further evidences are needed in order to better assess the optimal dose, the effectiveness and the safety of rFVI-Ia in such critical bleeding conditions.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins